Aripiprazole Tablet
Product Images NDC 68788-7063

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-7063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazoletablets 20mg (Image Containerlabel 20)

Label for Aripiprazole Tablets 20 mg oral tablets, generic for Abilify. The label shows that each tablet contains 20 mg of aripiprazole, USP. It includes manufacturer information as Torrent Pharmaceuticals Limited and directions for use in English and Spanish. The label also contains a caution about federal law prohibiting drug transfer and storage instructions.*

FDA Label Image

Image 1 (Image Fig1 Effectofotherdrug Arip)

A chart titled 'The effects of other drugs on aripiprazole pharmacokinetics' illustrating fold changes and 90% confidence intervals in aripiprazole exposure (AUC and Cmax) with various interacting drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). The x-axis shows change relative to the reference without interacting drug.*

FDA Label Image

Image 2 (Image Fig2 Effectofotherdrug Dehydroarip)

A figure titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics' showing a horizontal bar chart with fold change and 90% confidence intervals. It compares the impact of various drugs (CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others including valproate, lithium, lorazepam) on aripiprazole pharmacokinetic parameters AUC and Cmax relative to a reference without interacting drugs.*

FDA Label Image

Image 3 (Image Fig3 Effectofarip Otherdrug)

A pharmacokinetic chart illustrating the effects of aripiprazole on the pharmacokinetics of various other drugs including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The graph shows fold changes and 90% confidence intervals in variables such as AUC and Cmax, plotted relative to a reference without the interacting drug.*

FDA Label Image

Image 4 (Image Fig4 Effectofintrinsicfactor Arip)

A chart titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing fold change and 90% confidence intervals for aripiprazole pharmacokinetic parameters (AUC and Cmax). The factors compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment against reference groups. The x-axis represents change relative to reference from 0.5 to 3.0.*

FDA Label Image

Image 5 (Image Fig5 Effectofintrinsicfactor Dehydroarip)

A pharmacokinetic effect figure showing the impact of intrinsic factors on dehydro-aripiprazole levels. It compares fold changes and 90% confidence intervals for CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment, with change relative to reference on the x-axis and AUC and Cmax parameters on the y-axis.*

FDA Label Image

Fig 6 (Image Fig6 Schizophreniastudy 5)

Kaplan-Meier curve showing the cumulative proportion of patients with relapse over time in a schizophrenia study. The graph compares two groups: aripiprazole (blue solid line) and placebo (red dashed line), with relapse proportion on the y-axis and days from randomization on the x-axis. Below the x-axis, the number of subjects at risk for each group is provided over the study period.*

FDA Label Image

7 (Image Fig7 Bipolarstudy 7)

A Kaplan-Meier curve showing the cumulative proportion of patients with relapse over days from randomization in a bipolar study. The graph compares relapse rates between patients treated with aripiprazole and placebo, with aripiprazole represented by a solid blue line and placebo by a dashed red line. The x-axis shows days from randomization, and the y-axis indicates the proportion with relapse. A table below the graph lists the number of subjects at risk at various time points for both groups.*

FDA Label Image

8 (Image Fig8 Bipolarstudy 8)

A Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse to any mood event in a bipolar study. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Two curves compare Abilify (aripiprazole) in blue and placebo in red, with patient numbers at risk listed below the x-axis.*

FDA Label Image

9 (Image Fig9 Tourettesdisorderstudy1)

A line graph titled 'Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette's Disorder Study 1)' showing change in YGTSS total tic score from baseline over 8 weeks. The graph compares three groups: ARIPLOW, ARIPHIGH, and PLACEBO, with Y-axis values ranging from 0 to -15 and X-axis representing weeks of treatment from 0 to 8.*

FDA Label Image

Image (Image Logo Medguide)

FDA Label Image

Logo (Image Logo Pi)

FDA Label Image

Description Image (Image Structure)

Chemical structure of aripiprazole showing its detailed molecular framework including dichlorophenyl, piperazine, and quinolinone moieties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.